Four drugs under Shanghai Junshi Biosciences (HKG:1877, SHA:688180) were included in China's National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance list, according to a Sunday disclosure on the Hong Kong bourse.

The pharmaceutical company's Shanghai and Hong Kong shares both rose less than 1% during Monday's afternoon trade.

The drugs included on the list are toripalimab injection or Tuoyi, adalimumab injection or Junmaikang, deuremidevir hydrobromide tablets or Mindewei, and ongericimab injection or Junshida.

Tuoyi is the only anti-PD-1 monoclonal antibody on the list for the treatment of renal cancer, triple-negative breast cancer and melanoma.